Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q3 2022 · 10-Q
Revenue$1.97M$1.97M−0.6% vs Q3 2021 Net Income-$790.77K-$790.77KN/M vs Q3 2021 EPS Diluted-$0.16-$0.16N/M vs Q3 2021 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flowderived$219,123N/M Free Cash Flowderived-$33,427N/M Margins · derivedGross margin-7.0%+8.0 pt vs Q3 2021
Operating margin-35.0%+3.5 pt vs Q3 2021
Net margin-40.2%+1.6 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end